Current as of December 03, 2023
Pulmonary fibrosis that develops within a subpopulation of patients with rheumatoid arthritis is a disorder of unknown etiology. Although previous reports suggest that some individuals with rheumatoid arthritis have a genetic predisposition to the development of fibrotic lung disease, genetic factors have not been clearly identified. It is the intent of this clinical protocol to identify genetic polymorphisms in individuals with pulmonary fibrosis and rheumatoid arthritis.
- INCLUSION CRITERIA:
- Individuals 21 years of age or older with any of the following:
- RA (based on 1987 American College of Rheumatology Revised Criteria for the Classification of RA) with PF (biopsy-proven), or
- RA-only, or
- Biopsy-proven idiopathic PF-only, or
- Healthy research volunteers.
- EXCLUSION CRITERIA:
- Individuals with any of the following:
- Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).
- Chronic pulmonary disorders other than pulmonary fibrosis.
- Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).
- Non-rheumatoid arthritis.
- Viral infections associated with PF (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, United States
All reviews come from applied patients